Royalty Report: Drugs, Delivery, Biotechnology – Collection: 5407

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 10

Primary Industries

  • Drugs
  • Delivery
  • Biotechnology
  • Pharmaceuticals
  • Cancer
  • Therapeutic
  • Food
  • Beverages
  • Nutraceutical
  • HIV / AIDs
  • cardiac
  • Disease
  • Immune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5407

License Grant
The Licensor has entered into agreement with the Licensee which is developing several potential products which are vaccine based.
Field of Use
The Licensee wishes to use a combination of liposomes or cochleates in conjunction with Sendai vital proteins and its HIV synthetic peptides to create an EradicAide HIV Vaccine.
The EVP will be used to research and develop such formulation(s) of EradicAide HIV Vaccine to determine feasibility for human clinical trials and eventual marketing.
The Licensee proposes that successful development of EradicAide HIV Vaccine could result in various types of formulations based upon an injectable or oral dosage form:
1) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an injectable form
2) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an oral form.

To the extent that the Licensee utilizes the Licensor's Bioral drug delivery technology, Bioral Cochleate Technology seeks to use an established, safe nutriceutical, phosphatidyl serine, to nano-encapsulate by means of our patented Cochleate structures, drugs to achieve oral delivery of therapeutic nutriceuticals that normally require injection (such as molecules with poor water solubility, large hydrophilic molecules, and protein and peptide biopharmaceuticals) and to potentially reduce toxicity and side effects frequently associated with established therapeutics.

IPSCIO Record ID: 5541

License Grant
Licensor has grants an exclusive worldwide sublicense to exploit the technology for all opportunities in the processed food and beverage industry for both human and animal consumption.  Both parties are U.S. corporations.  The grant includes the rights to use registered trademark Bioral in connection with the creation of consumable products. Licensee is wholly owned subsidiary of Licensor.
License Property
The technology involves cochleates, cochleate derivatives, and proteoliposomes, and nano-encapsulation.  Cochleate delivery vehicles represent a new technology platform for oral and systemic delivery of clinically important drugs that possess poor bioavailability.

Cochleate delivery vehicles wrap-up or encapsulate the drug, rather than chemically bond with the included drug.  A few of the US patents include: 1) Liposome Methods and Composition 4,663,161 2) Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles 4,871,488  Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same 3. Stabilizing And Delivery Means of Biological Molecules 5,643,574.  Exhibit has excellent description of technology.  The exhibit does not explain, but the original licensor is the University of Medicine and Dentistry of New Jersey who granted an exclusive worldwide license to develop the cochleate technology and in some cases co-owns the patents with the corporation.

Trademark 'Bioral'

Field of Use
Field shall mean delivery of Consumable Products to all living systems for processed foods applications for both human and Animal consumption.

IPSCIO Record ID: 266802

License Grant
Licensor grants an exclusive license throughout the Territory, with the right to grant sublicenses to make, use or sell Licensed Technology and Licensed Patents in the Field for research, development and commercialization of one Polynucleotide Product and one ~ Product or Nutraceutical Product.

Licensor grants to a worldwide, non-exclusive license to Licensor Intellectual Property.

License Property
Licensor has rights to certain Licensed Technology relating to cochleates, cochleate derivatives, and proteoliposomes, and nano-encapsulation.

Patented Bioral® is a cochleate drug delivery technology, designed for a potentially broad base of applications.

Field of Use
Licensee recognizes that the Licensed Technology represents a valuable means of delivering Component Products for the use and/or sale in the treatment or prevention of human and/or animal diseases.

'Component Product' shall mean any Polynucleotide Product, Drug Product or Nutraceutical
Product.

IPSCIO Record ID: 203340

License Grant
Licensor grants to the Italian Licensee the sole and exclusive license under the Patents and the Know-How to use, offer for sale, sell, develop, manufacture, and have manufactured the Products in the Field in the Territory, with the right to grant sublicenses relating only to Products in the Field in the Territory.
License Property
The patents and know-how are for Liposome Methods and Composition, Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles, Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same,  Stabilizing And Delivery Means of Biological Molecules, Protein-Lipid Vesicles and Autogenous Vaccine Comprising The Same, Nanocochleate Formulations, Process of Preparation and Method of Delivery of Pharmaceutical Agents, Cochleates From Purified Soy Phosphatidylserine, Geodate Delivery Vehicles, Rigid Liposomal Compositions, Cochleate Preparations of Fragile Nutrients, Antisense Cochleates, Cochleates Including Aggregation Inhibitors, Novel Encochleation Methods, Cochleates and Methods of Use, Replacement Enzyme Cochleates, Apoprotein Cochleate Compositions, Cochleate Compositions Directed Against Expression of Proteins, and, Novel Encochleation Methods, Cochleates and Methods of Use.

Products means any product in finished pharmaceutical form for use and sale in the Field containing the Compounds formulated with and incorporating the Patents and Know-How and covered by a Valid  Claim.

Field of Use
Field means solely for use of the Products in oncology, cardiovascular and immunology pharmaceuticals.

It is Licensee's intention to use Licensor's licensed, Bioral(TM) nanocochleate drug delivery technology to provide for oral delivery of pharmaceutical products incorporating these compounds.

IPSCIO Record ID: 5404

License Grant
Universities hereby grant to us, without the need for any further action, an exclusive license throughout the Territory, with the right to grant sublicenses to manufacture, use and sell Products in the Field, under the Licensed Technology and Licensed Patents. Universities hereby grant to us, without the need for any further action, an exclusive license throughout the Territory, with the right to grant sublicenses to manufacture, use and sell Products in the Field, under the Licensed Technology and Licensed Patents.
License Property
Universities have exclusive rights to certain technology relating to cochleates, liposomes and proteoliposomes.

Under the license agreement, we and the Universities have also jointly patented certain aspects of the cochleate technology and co-own such patents with them.  Our proposed drug delivery technology varies from competitors by encapsulating or wrapping the selected drug in a jellyroll-like structure termed a cochleate cylinder.  All of the components of the cochleate cylinder are naturally occurring substances.  We believe that the cochleate cylinder provides an effective delivery mechanism without forming a chemical bond, or otherwise chemically altering, the drug.   When wrapped in our cochleate cylinders, we anticipate that these drugs may be marketed under our brand name, Bioral.

LICENSED PATENTS:

United States Patent Number 4,663,161 Issued May 5, 1987

United States Patent Number 4,871,488 Issued October 3, 1989

United States Patent Application Serial Number 08/130,986 Filed

October 4, 1993. Corres. International Application

PCT/US94/10913 Filed September 30, 1994.

United States Patent Application Serial Number 08/394,70 Filed

February 22, 1995. Corres. International Application, PCT

Field of Use
'Field' shall mean cochleates, liposomes and proteoliposomes for all living systems, including human, animal, plant, microbial, life science, health care, nutrition and cosmetics applications of the Licensed Technology.

IPSCIO Record ID: 28542

License Grant
Licensor grants to Licensee an exclusive right and license, with a right to sublicense to Affiliates and others in accordance with the provisions hereof, in the Territory under the Licensed Patent and Licensed Information to make, have made, use, import, sell, have sold and offer to sell Licensed Products in the Field.
License Property
Licensor has rights to technology relating to cochleates, liposomes and proteoliposomes which will elicit an antigen specific immune response in humans and which are used in the formulation of human vaccines and has rights to patent applications and patents related to said technology.

Application serial #08/130,986 Protein or Peptide-Cochleate vaccines and methods of immunizing using the same.

Field of Use
Field means vaccines designed to induce (not limited to type of immune modulation) an antigen(s) specific immune response in humans; including vaccines to prevent or treat allergies (Type I hypersensitivity reaction), but not including vaccines to treat autoimmunity nor vaccines made from patient specific antigen(s) for patient specific therapy.

IPSCIO Record ID: 27091

License Grant
The University hereby grants to Licensee the exclusive right and license in the Territory to practice under the Patent Rights and to make, have made, use, lease, sell and import Licensed Products and to practice the Licensed Processes.   Licensee shall have the right to enter into sublicensing agreements for the rights, privileges and licenses granted hereunder. Certain Patent Rights (as later defined herein) relating to Case No. 6388, Polymerized Liposomes with Enhanced Stability.
License Property
Polymerized Liposomes with Enhanced Stability is a technology that is used for the oral and mucosal delivery of vaccines, allergens, proteins and peptides via Polymerized Liposomes (the Orasome (TM) technology).
Field of Use
This Orasome(TM) technology is based on lipids that can easily be assembled into structures that efficiently capture drugs and proteins, bypassing the destructive action of stomach acids and intestinal degradative enzymes — while being taken up efficiently by crucial key cells in the intestinal tract. Because of the unique ability of these cross-linked liposomes to withstand the cleansing activity of bile salts, digestive enzymes, and gastric acids, this proprietary liposomal technology may be utilized practically and commercially for the oral delivery of many therapeutics.

IPSCIO Record ID: 27964

License Grant
The Irish Licensee entered into a purchase and license agreement with the Irish Licensor, to license several oral drug delivery technologies, including a large intellectual property portfolio, which included the GIPET and GIRES delivery technologies, as well as a pipeline of future products and technologies relating to oral vaccine delivery and targeting ligands.
Field of Use
The rights granted apply to the healthcare industry relating in the development of improved oral dosage forms of drugs with poor bioavailability.

IPSCIO Record ID: 7076

License Grant
Licensor hereby grants to Licensee an exclusive license throughout the Territory, with the right to grant sublicenses to make, use or sell Licensed Products in the Field.
License Property
Licensed Product shall mean a Product in the form of (a) antifungal preparations (including Amphotericin B preparations) for mucosal surface application for the indications of chronic sinusitis and asthma; and (b) transmucosal vaccine preparations for the indications of chronic sinusitis and asthma.

Antifungal Products shall mean any and all products covered by the patent rights licensed to Licensee by MAYO.

Technology refers to encochleated formulation of amphotericin B for topical treatments for CRS and asthma.

Licensed Patents

Docket No./Title/

  
Appln No./Patent No.
Country

BSZ-005: Liposome Methods and Composition US 4,663,161

BSZ-005DV: Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles
US 4,871,488

BSZ-006: Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same US 5,643,574

BSZ-006CP: Stabilizing Delivery Means of Biological MoleculesInt’I (PC) US94/10913

Field of Use
Field shall mean the field of any topical antifungal (including Amphotericin B) for mucosal surface application for the indications of chronic sinusitis and asthma covered by patents licensed to Licensee by the Mayo Clinic (MAYO), and transmucosal vaccine applications covered by a patent held by MAYO for the indications of chronic sinusitis and asthma.

IPSCIO Record ID: 4505

License Grant
The Licensor granted an exclusive license to develop pharmaceutical products using certain molecule(s) based on Licensee’s technology and the Licensor’s proprietary technology (PolyXen®, OncoHist™ and ImuXen®) that prolongs the active life and/or improves the pharmacokinetics of certain therapeutic proteins and peptides (as well as conventional drugs).
License Property
PolyXen® is an enabling technology that utilizes Polysialic Acid (“PSA”), a biopolymer, a chain of sialic acids which is a natural constituent of the human body. PSA is designed to extend the half-life in circulation in the human body for a variety of existing drug molecules and, thereby, to create potentially superior next generation drug candidates. OncoHist™ is a novel therapeutic platform that utilizes the properties of the human histone H1.3 (“H1.3”) for the development of drug candidates for the treatment of a broad range of cancer indications. OncoHist™, unlike many competing oncology therapies, is based on a molecule occurring naturally in the human body, in the cell nucleus, and is therefore expected to be less toxic and immunogenetic than other oncology therapies. ImuXen® is a novel liposomal co-entrapment encapsulation technology designed to create new vaccines and improve the use and efficacy of certain existing vaccines for use in the human body. The technology is based on the co-entrapment of the nominated antigen(s) in a liposomal vesicle, a design that is intended to maximize both cell and immune system mediated responses.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.